209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.
52 citations
,
September 2012 in “Oncogene”
10 citations
,
July 2021 in “Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin” LRIG1 is linked to better survival in Merkel cell carcinoma.
73 citations
,
April 2013 in “Stem cells” LGR5 helps maintain corneal cell characteristics and prevents unwanted changes by controlling specific cell signaling pathways.
3 citations
,
August 2022 in “International Journal of Molecular Sciences” TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.
11 citations
,
May 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Identical p53 gene mutations in different cancers suggest the need for careful treatment.
9 citations
,
May 2019 in “Experimental Cell Research” HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.
July 2025 in “Journal of Investigative Dermatology” July 2026 in “Expert Review of Clinical Immunology” Targeting specific immune cells may improve treatment for alopecia areata.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
August 2012 in “Nature Cell Biology” A pathway helps maintain long telomeres in both stem and cancer cells.
21 citations
,
May 2014 in “Toxicological Sciences” Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.
288 citations
,
January 2001 in “Journal of Biological Chemistry” Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
2 citations
,
December 2019 in “Al-ʻulūm al-ṣaydalāniyyaẗ” The CTLA-4 gene change studied does not affect Polycystic Ovarian Syndrome in the women tested.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
16 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.
18 citations
,
July 2013 in “Journal of Leukocyte Biology” Nonimmunogenic forms of keratins K71 and K31 can delay and prevent alopecia areata.
11 citations
,
January 2022 in “Experimental Dermatology” Severe CCCA may be biologically and clinically different from milder forms.
September 2025 in “Annals of African Medicine” ETS2 is crucial in squamous cell carcinoma development and could be a therapeutic target.
July 2024 in “Journal of Investigative Dermatology” 178 citations
,
April 2011 in “Journal of Clinical Investigation” Basal cell carcinomas in mice can start from hair follicle stem cells and other skin cell types, depending on signaling levels.
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Normal cells outcompete and remove mutant cells in the pancreas with the help of the EphA2 receptor.
10 citations
,
December 2015 in “International Journal of Molecular Sciences” PDCD4 is important for controlling skin cell growth and healing.
March 2026 in “Tissue Engineering and Regenerative Medicine” M-CSF-stimulated myeloid cells can turn into skin cells and help heal wounds and regrow hair.
October 2025 in “Cell Death and Disease” CD271 is crucial for maintaining healthy skin and preventing inflammation.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.